Camp4 Therapeutics Corporation
CAMP
$2.05
$0.063.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | 86.29% | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 86.29% | -- | -- | -- | |
| Cost of Revenue | -4.40% | -- | -- | -- | |
| Gross Profit | 5.19% | -- | -- | -- | |
| SG&A Expenses | 28.40% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 2.89% | -- | -- | -- | |
| Operating Income | -2.33% | -- | -- | -- | |
| Income Before Tax | -5.07% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -5.07% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -5.07% | -- | -- | -- | |
| EBIT | -2.33% | -- | -- | -- | |
| EBITDA | -2.37% | -- | -- | -- | |
| EPS Basic | 38.03% | -- | -- | -- | |
| Normalized Basic EPS | 38.03% | -- | -- | -- | |
| EPS Diluted | 38.03% | -- | -- | -- | |
| Normalized Diluted EPS | 38.03% | -- | -- | -- | |
| Average Basic Shares Outstanding | 1,087.70% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 1,087.70% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |